Impact of polyplex micelles installed with cyclic RGD peptide as ligand on gene delivery to vascular lesions

Gene Therapy

Volumn 19, Issue 1, 2012, Pages 61-69

  Kagaya, H ^a   Oba, M ^b   Miura, Y ^a   Koyama, H ^a   Ishii, T ^a   Shimada, T ^a   Takato, T ^a   Kataoka, K ^a   Miyata, T ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

cyclo(RGDfK) peptide; gene delivery; neointimal hyperplasia; polyplex micelle; vascular lesion

Indexed keywords

ALPHAVBETA5 INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; CLATHRIN; ETHYLENEDIAMINE; LYSOSOME ENZYME; MACROGOL; PLASMID DNA; POLYCATION; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CAROTID ARTERY; CAROTID ARTERY INJURY; CAVEOLA; CELL TRANSPORT; COMPLEX FORMATION; CONTROLLED STUDY; ENDOCYTOSIS; ENDOSOME; ENDOTHELIUM CELL; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; IN VIVO STUDY; LYSOSOME; MEDIATOR; MICELLE; MICELLIZATION; NEOINTIMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; POLYMERIZATION; POLYPLEX MICELLE; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELL;

ANIMALS; CAROTID ARTERIES; CAROTID ARTERY INJURIES; CELLS, CULTURED; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTEGRIN ALPHAVBETA3; LIGANDS; MICELLES; MODELS, ANIMAL; PEPTIDES, CYCLIC; PLASMIDS; POLYETHYLENE GLYCOLS; PROTEINS; RATS; RECEPTORS, VITRONECTIN;

RATTUS;

EID: 84855452919     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.74     Document Type: Article

References (46)

1. Taniyama Y, Tachibana K, Hiraoka K, Namba T, Yamasaki K, Hashiya N et al. Local delivery of plasmid DNA into rat carotid artery using ultrasound. Circulation 2002; 105: 1233-1239. (Pubitemid 34225826)
2. Nishikage S, Koyama H, Miyata T, Ishii S, Hamada H, Shigematsu H. In vitro electroporation enhances plasmid-based gene transfer of basic fibroblast growth factor for the treatment of ischemic limb. J Surg Res 2004; 120: 37-46. (Pubitemid 38686528)
3. Tomanin R, Scarpa M. Why do we need new gene therapy viral vectors? Characteristics, limitations and future perspectives of viral vector transduction. Curr Gene Ther 2004; 4: 357-372. (Pubitemid 39534752)
4. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007-an update. J Gene Med 2007; 10: 833-842. (Pubitemid 47543250)
5. Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discovery 2005; 4: 581-593. (Pubitemid 40975711)
6. Mastrobattista E, van der Aa MA, Hennink WE, Crommelin DJA. Artificial viruses: a nanotechnological approach to gene delivery. Nat Rev Drug Discovery 2006; 5: 115-121.
7. Wagner E, Ogris M, Zauner W. Polysine-based transfection systems utilizing receptormediated delivery. Adv Drug Deliv Rev 1998; 30: 97-113. (Pubitemid 28201908)
8. Oupicky D, Konak C, Ulbrich K, Wolfert MA, Seymour LW. DNA delivery systems based on complexes of DNA with synthetic polycations and their copolymers. J Control Release 2000; 65: 149-171. (Pubitemid 30122923)
9. Pedroso de Lima MC, Simoes S, Pires P, Faneca H, Duzgunes N. Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications. Adv Drug Delivery Rev 2001; 47: 277-294. (Pubitemid 32324118)
10. Merdan T, Kopecek J, Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Delivery Rev 2002; 54: 715-758. (Pubitemid 35247524)
11. Ogris M, Brunner S, Schuller S, Kircheis R, Wagner E. PEGylated DNA/transfection-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Therapy 1999; 6: 595-605. (Pubitemid 29192668)
12. Oupicky D, Konak D, Dash PR, Seymour LW, Ulbrich K. Effect of albumin and polyanion on the structure of DNA complexes with polycation containing hydrophilic nonionic block. Bioconjug Chem 1999; 10: 764-772. (Pubitemid 29456362)
13. Kakizawa Y, Kataoka K. Block copolymer micelles for delivery of gene and related compounds. Adv Drug Delivery Rev 2002; 54: 203-222. (Pubitemid 34230442)
14. Katayose S, Kartaoka K. Water-solubule polyion complex association of DNA and poly (ethylene glycol)-poly(L-lysine) block copolymer. Bioconjug Chem 1997; 8: 702-707. (Pubitemid 27416084)
15. Osada K, Kataoka K. Drug and gene delivery based on supramolecular assembly of PEG-polypeptide hybrid block copolymers. Adv Polym Sci 2006; 202: 113-153.
16. Itaka K, Harada A, Nakamura K, Kawaguchi H, Kataoka K. Evaluation by fluorescence resonance energy transfer of the stability of nonviral gene delivery vectors under physiological conditions. Biomacromolecules 2002; 3: 841-845.
17. Harada-Shiba M, Yamauchi K, Harada A, Takamizawa I, Shimokado K, Kataoka K. Polyion complex micelles as vectors in gene therapy-pharmakokinetics and in vivo gene transfer. Gene Therapy 2002; 9: 407-414. (Pubitemid 34414039)
18. Itaka K, Yamanouchi K, Harada A, Nakamura K, Kawaguchi H, Kataoka K. Polyion complex micelles from plasmid DNA and poly(ethylene glycol)-poly(L- lysine) block copolymer as serum-tolerable polyplex system: physicochemical properties of micelles relevant to gene transfection efficiency. Biomaterials 2003; 24: 4495-4506. (Pubitemid 36960144)
19. Han M, Bae Y, Nishiyama N, Miyata K, Oba M, Kataoka K. Transfection study using multicellular tumor spheroids for screening non-viral polymeric gene vectors with low cytotoxicity and high transfection efficiencies. J Control Release 2007; 121: 38-48. (Pubitemid 47126063)
20. Akagi D, Oba M, koyama H, Nishiyama N, Fukushima S, Miyata T et al. Biocompatible micellar nanovectors achieve efficient gene transfer to vascular lesions without cytotoxicity and thrombus formation. Gene Therapy 2007; 14: 1029-1038. (Pubitemid 46965272)
21. Kanayama N, Fukushima S, Nishiyama N, Itaka K, Jang W-D, Miyata K et al. A PEGbased biocompatible block catiomer with high buffering capacity for the construction of polyplex micelles showing efficient gene transfer toward primary cells. Chem Med Chem 2006; 1: 439-444.
22. Itaka K, Ishii T, Hasegawa Y, Kataoka K. Biodegradable polyamino acid-based polycations as safe and effective gene carrier minimizing cumulative toxicity. Biomaterials 2010; 31: 3707-3714.
23. Miyata K, Oba M, Nakanishi M, Fukushima S, Yamasaki Y, Koyama H et al. Polyplexes from poly(aspartamide) bearing 1,2-diaminoethane side chains induce pH-selective, endosomal membrane destabilization with amplified transfection and negligible cytotoxicity. J Am Chem Soc 2008; 130: 16287-16294.
24. Wakebayashi D, Nishiyama N, Yamasaki Y, Itaka K, Kanayama N, Harada A et al. Lactose-conjugated polyion complex micelles incorporating plasmid DNA as a targetable gene vector system: their preparation and gene transfecting efficiency against cultured HepG2 cells. J Control Release 2004; 95: 653-664. (Pubitemid 38340512)
25. Suh W, Han SO, Yu L, Kim SW. An angiogenic endothelial-cell-targeted polymeric gene carrier. Mol Ther 2002; 6: 664-672. (Pubitemid 35363699)
26. Ogris M, Walker G, Blessing T, Kircheis R, Wolschek M, Wagner E. Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. J Control Release 2003; 91: 173-181. (Pubitemid 37288888)
27. Haubner R, Gratias R, Diefenbach B, Goodman SL, Jonczyk A, Kessler H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin avb3 antagonist. J Am Chem Soc 1996; 118: 7461-7472. (Pubitemid 26279800)
28. Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin avb3 for angiogenesis. Science 1994; 264: 569-571. (Pubitemid 24185862)
29. Kim WJ, Yockman JW, Lee M, Jeong JH, Kim YH, Kim SW. Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis. J Control Release 2005; 106: 224-234. (Pubitemid 41140097)
30. Kim WJ, Yockman JW, Jeong JH, Christensen LV, Lee M, Kim YH et al. Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice. J Control Release 2006; 114: 381-388. (Pubitemid 44310812)
31. Choi ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S et al. Inhibition of neointimal hyperplasia by blocking alpha V beta 3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg 1994; 19: 125-134. (Pubitemid 24060187)
32. Hoshiga M, Alpers CE, Smith LL, Giachelli CM, Schwartz SM. Alpha-v beta-3 integrin expression in normal and atherosclerotic artery. Circ Res 1995; 77: 1129-1135.
33. van der Zee R, Murohara T, Passeri J, Kearney M, Cheresh DA, Isner JM. Reduced intimal thickening following alpha(v)beta3 blockade is associated with smooth muscle cell apoptosis. Cell Adhes Common 1998; 6: 371-379. (Pubitemid 29056018)
34. Srivatsa SS, Fitzpatrick LA, Tsao PW, Reilly TM, Holmes Jr DR, Schwartz RS et al. Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation. Cardiovasc Res 1997; 36: 408-428. (Pubitemid 28037364)
35. Kokudo T, Uchida H, Choi ET. Integrin avb3 as a target in the prevention of neointimal hyperplasia. J Vasc Surg 2007; 45: 33-38.
36. Oba M, Fukushima S, Kanayama N, Aoyagi K, Nishiyama N, Koyama H et al. Cyclic RGD peptide-conjugated polyplex micelles as a targetable gene delivery system directed to cells possessing avb3 and avb5 integrins. Bioconjugate Chem 2007; 18: 1415-1423.
37. Oba M, Aoyagi K, Miyata K, Matsumoto Y, Itaka K, Nishiyama N et al. Polyplex micelles with cyclic RGD peptide ligands and disulfide cross-links directing to the enhanced transfection via controlled intracellular trafficking. Mol Pharm 2008; 5: 1080-1092.
38. Grosse S, Aron Y, Thevenot G, Francosis D, Monsigny M, Fajac I. Potocytosis and cellular exit of complexes as cellular pathway for gene delivery by polycations. J Gene Med 2005; 7: 1275-1286. (Pubitemid 41555434)
39. Wickman TJ, Filardo EJ, Cheresh DA, Nemerow GR. Integrin avb5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol 1994; 127: 257-264.
40. Wary KK, Mainiero F, Isakoff SJ, Marcantonio EE, Giancotti FG. The adaptor protein Shc couples a class of integrin to the control of cell cycle progression. Cell 1996; 87: 733-743. (Pubitemid 26386946)
41. Wary KK, Mariotti A, Zurzolo C, Giancotti FG. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell 1998; 94: 625-634. (Pubitemid 28427581)
42. Marinelli L, Gottschalk KE, Meyer A, Novellino E, Kessler H. Human integrin avb5: homology modeling and ligand binding. J Med Chem 2004; 47: 4166-4177. (Pubitemid 39045424)
43. Oba M, Miyata K, Osada K, Christie RJ, Sanjoh M, Li W et al. Polyplex micelles prepared from o-cholesteryl PEG-polycation block copolymers for systemic gene delivery. Biomaterials 2011; 32: 652-663.
44. Stary HC, Blankenhorn DH, Chandler AB, Glagov S, Insull Jr W, Richardson M et al. A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1992; 85: 391-405.
45. Guzman RJ, Lemarchand P, Crystal RG, Epstein SE, Finkel T. Efficient and selective adenovirus-mediated gene transfer into vascular neointima. Circulation 1993; 88: 2838-2848. (Pubitemid 23360211)
46. Pelkmans L, Kartenbeck J, Helenius A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular transport pathway to the ER. Nat Cell Biol 2001; 3: 473-483. (Pubitemid 32422083)